| Date |
Title |
Rating |
| 2012-06-29 |
A.P. Pharma announces additional data from APF530 Phase 3 study on CINV |
None |
| 2012-06-29 |
Lexicon announces results from two initial trials of LX4211 for type 2 diabetes |
None |
| 2012-06-29 |
Drug trial participants should be better informed about benefits and side-effects of placebos |
None |
| 2012-06-29 |
Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens |
None |
| 2012-06-29 |
New drug for Type 2 diabetes results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk for patients |
None |
| 2012-06-29 |
Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV |
None |
| 2012-06-29 |
Results from Access’ MuGard Phase 4 trial on oral mucositis |
None |
| 2012-06-28 |
LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress |
None |
| 2012-06-28 |
Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy |
None |
| 2012-06-28 |
Full results from Derma Sciences’ DSC127 Phase 2 trial on diabetic foot ulcers |
None |
| 2012-06-28 |
Anthera announces results from blisibimod Phase 2b study on SLE |
None |
| 2012-06-27 |
Combination of radiation therapies effectively treat prostate cancer, lower chances of recurrence |
None |
| 2012-06-27 |
SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation |
None |
| 2012-06-27 |
Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma |
None |
| 2012-06-27 |
Vitamin D and calcium supplements could increase risk of kidney stones |
3 |
| 2012-06-27 |
Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer |
None |
| 2012-06-27 |
First clinical trial to test cardiac drug regimen for DMD |
None |
| 2012-06-27 |
RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars |
None |
| 2012-06-27 |
BioSpecifics commences XIAFLEX Phase II trial in human lipoma |
None |
| 2012-06-26 |
Positive results from Antares Pharma's VIBEX MTX human factors usability study for RA |
5 |
| 2012-06-26 |
Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults |
None |
| 2012-06-26 |
Investigational parathyroid hormone replacement effectively treats hypoparathyroidism |
None |
| 2012-06-26 |
Clinical trial to examine functional benefits of combined therapy against stroke |
None |
| 2012-06-26 |
New drug better than chemotherapy for skin cancer patients |
None |
| 2012-06-26 |
Experimental medication increases muscle strength in cancer patients with low testosterone levels |
None |
| 2012-06-26 |
Combination of liraglutide and insulin controls blood sugar in obese adults with T1D |
None |
| 2012-06-26 |
Sitagliptin appears to reduce severity of reactive hypoglycemia |
None |
| 2012-06-26 |
Male hormonal contraceptives applied daily to the skin reduce sperm production |
None |
| 2012-06-26 |
KaloBios’ KB001 shows promise against Pa pneumonia |
None |
| 2012-06-26 |
Experimental medication helps overweight patients with diabetes shed pounds |
None |
| 2012-06-26 |
CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC |
None |
| 2012-06-26 |
Sinovac provides update on EV71 vaccine Phase III trial on HFMD |
None |
| 2012-06-25 |
Standard aspirin dose may not protect diabetics against blood clots |
None |
| 2012-06-25 |
Degludec effectively lowers blood glucose with lower risk for hypoglycemia |
None |
| 2012-06-25 |
NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product |
None |
| 2012-06-25 |
Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder |
None |
| 2012-06-25 |
Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes |
None |
| 2012-06-25 |
Study reinforces importance of educating parents and other caregivers of children with food allergy |
None |
| 2012-06-25 |
Major weight loss an added benefit of testosterone replacement therapy for men |
2 |
| 2012-06-23 |
Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome |
5 |
| 2012-06-23 |
Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer |
None |
| 2012-06-23 |
AbGenomics raises $11 million in current financing round |
None |
| 2012-06-22 |
Alexza resubmits ADASUVE NDA to U.S. FDA |
None |
| 2012-06-22 |
Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine |
None |
| 2012-06-22 |
Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma |
None |
| 2012-06-22 |
Iroko announces results from diclofenac Phase 3 study on post-surgical pain |
None |
| 2012-06-22 |
Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting |
None |
| 2012-06-21 |
Study to test NAC and aspirin for people diagnosed with bipolar disorder |
None |
| 2012-06-21 |
Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD |
5 |
| 2012-06-21 |
Omega-3 fatty acid supplements can reduce inflammation in overweight older adults |
None |
| 2012-06-20 |
Furiex initiates MuDelta Phase III studies in IBS-D |
None |
| 2012-06-19 |
Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain |
None |
| 2012-06-19 |
e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer |
None |
| 2012-06-19 |
Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation |
None |
| 2012-06-19 |
New patent filed for VAC-3S, an immunotherapy for treating HIV infections |
None |
| 2012-06-19 |
Antiarrhythmic short-term treatment useful for some patients |
None |
| 2012-06-19 |
Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress |
None |
| 2012-06-18 |
Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS |
None |
| 2012-06-18 |
CINJ commences enrollment in three-drug combination trial for breast cancer |
None |
| 2012-06-18 |
Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma |
None |
| 2012-06-18 |
Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC |
None |
| 2012-06-18 |
Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL |
None |
| 2012-06-18 |
DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy |
None |
| 2012-06-18 |
UW initiates enrollment in tosedostat phase II combination study for AML, MDS |
None |
| 2012-06-18 |
Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL |
None |
| 2012-06-18 |
Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL |
None |
| 2012-06-18 |
Impressive results from blinatumomab Phase 2 study on B-precursor ALL |
None |
| 2012-06-16 |
Promising results from single iron dose study for fatigue treatment in iron deficient women |
None |
| 2012-06-16 |
Combination of low-dose vitamin D and calcium does not reduce fracture risk in women |
None |
| 2012-06-16 |
St. Michael's to investigate new treatments for prevention of brain injury complications |
None |
| 2012-06-16 |
Large-scale trial of vaginal ring that releases anti-HIV drug announced at health summit in London |
None |
| 2012-06-16 |
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML |
None |
| 2012-06-16 |
Study finds no evidence to support an effect of THC on MS progression |
None |
| 2012-06-16 |
Civitas commences CVT-301 Phase 2a trial in Parkinson's disease |
None |
| 2012-06-16 |
Less expensive ARV combination just as effective for women in developing countries as costlier ARVs, study shows |
None |
| 2012-06-15 |
Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM |
None |
| 2012-06-15 |
Changing guidelines threaten important HIV drug trial |
None |
| 2012-06-15 |
Positive top-line results from Teva’s GALA Phase III trial on RRMS |
None |
| 2012-06-15 |
TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer |
None |
| 2012-06-15 |
Antioxidant rhSOD reduces risk of blindness in extremely low gestational age newborns |
None |
| 2012-06-15 |
Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema |
None |
| 2012-06-15 |
Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection |
None |
| 2012-06-15 |
Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer |
None |
| 2012-06-14 |
Hay fever vaccine shows efficacy in phase IIa trial |
None |
| 2012-06-14 |
AB Science announces results from masitinib phase 2 study on MS |
None |
| 2012-06-14 |
Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL |
None |
| 2012-06-14 |
Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways |
None |
| 2012-06-14 |
IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine |
None |
| 2012-06-14 |
Sabin initiates novel human hookworm vaccine Phase 1 clinical trial |
None |
| 2012-06-14 |
NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC |
None |
| 2012-06-14 |
Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD |
5 |
| 2012-06-14 |
Azaya announces final results from ATI-1123 Phase I study on cancers |
None |
| 2012-06-14 |
EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012 |
None |
| 2012-06-13 |
Investigational Insomnia Medicine from Merck improved patients’ ability to fall and stay asleep according to new phase III Data |
None |
| 2012-06-13 |
ChromaDex’s pTeroPure safe for human consumption |
None |
| 2012-06-13 |
New combination therapy can help improve cure rates for neuroblastoma |
5 |
| 2012-06-13 |
Long-term insulin use does not increase risk of heart disease in people with diabetes |
None |
| 2012-06-13 |
VaxInnate commences VAX161 Phase I trial in pandemic avian influenza |
None |
| 2012-06-13 |
Acorda commences AMPYRA clinical study for post-stoke deficits |
3 |
| 2012-06-12 |
Almased helps patients with type 2 diabetes lose weight, gain better sugar control |
None |
| 2012-06-12 |
Initial trial results from KYTHERA’s second of two Phase III trials with ATX-101 |
None |
| 2012-06-12 |
Individuals on statins more likely to experience fatigue with exertion |
None |
| 2012-06-11 |
Theramine may reduce chronic low back pain |
None |
| 2012-06-11 |
FDA accepts Avanir IND for AVP-923 to treat agitation in patients with AD |
None |
| 2012-06-11 |
Positive results from Cara’s CR845 Phase II study on acute post-operative pain |
None |
| 2012-06-11 |
BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD |
None |
| 2012-06-11 |
Ampio’s CRO completes Optina clinical trial for DME |
None |
| 2012-06-11 |
Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes |
None |
| 2012-06-11 |
Zafgen announces new data from two Phase 1 studies of beloranib on obesity |
None |
| 2012-06-11 |
Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes |
None |
| 2012-06-11 |
Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery |
None |
| 2012-06-11 |
Cebix announces data from Ersatta Phase 1 study on type 1 diabetes |
None |
| 2012-06-11 |
Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes |
5 |
| 2012-06-11 |
Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes |
None |
| 2012-06-11 |
Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D |
None |
| 2012-06-11 |
Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA |
None |
| 2012-06-10 |
Lexicon presents six posters on LX4211 at ADA meeting |
None |
| 2012-06-08 |
CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B |
None |
| 2012-06-08 |
Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD |
None |
| 2012-06-08 |
Large-scale randomized treatment study on adrenocortical cancer |
None |
| 2012-06-08 |
Erivedge drug shows promise against advanced basal cell carcinoma |
None |
| 2012-06-08 |
Data from abatacept versus adalimumab Phase IIIb comparison study on RA |
None |
| 2012-06-08 |
Experimental drug tested against multi-drug resistant TB |
None |
| 2012-06-08 |
Banyan, Amarantus complete collaboration agreement related to TBI development program |
None |
| 2012-06-08 |
Sorrento receives $300,000 STTR grant to develop novel therapeutics against Staph infections |
None |
| 2012-06-08 |
NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012 |
None |
| 2012-06-08 |
MGH, HSG to conduct PBT2 clinical trial in Huntington's disease |
None |
| 2012-06-07 |
Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3 |
None |
| 2012-06-07 |
Clinical study shows positive effects of CAD106 vaccine against AD |
None |
| 2012-06-07 |
Biologic treatments reduce mortality risk in patients with rheumatoid arthritis |
None |
| 2012-06-07 |
Dengue fever vaccine 'may be in sight,' Reuters reports |
None |
| 2012-06-07 |
Clinical study demonstrates effectiveness of vismodegib in treating BCNS |
None |
| 2012-06-07 |
Savient announces results from KRYSTEXXA Phase III trials on gout-related kidney disease |
None |
| 2012-06-07 |
Debiopharm announces results from Debio 0932 Phase I study on cancer |
5 |
| 2012-06-07 |
ADACTA trial: Tocilizumab more effective than adalimumab in treating RA |
1.5 |
| 2012-06-06 |
AB Science announces data from development program of masitinib in GIST |
None |
| 2012-06-06 |
STELARA effectively reduces signs and symptoms of active psoriatic arthritis |
None |
| 2012-06-06 |
PhaseBio raises $48.4M in Series B financing |
None |
| 2012-06-06 |
Abbott announces results from HUMIRA Phase 3 study on axSpA |
None |
| 2012-06-06 |
Cardio-protective drug during cancer treatment may prevent heart damage in children |
None |
| 2012-06-06 |
Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma |
None |
| 2012-06-06 |
Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC |
None |
| 2012-06-06 |
Abbott commences elagolix Phase 3 trial in endometriosis |
None |
| 2012-06-06 |
New immune response data from Generex’s AE37 Phase II trial on breast cancer |
None |
| 2012-06-06 |
Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC |
None |
| 2012-06-05 |
Lilly announces final results from ALIMTA Phase III study on NSCLC |
4 |
| 2012-06-05 |
Three-drug regimen provides rapid, durable responses for multiple myeloma |
None |
| 2012-06-05 |
Soy protein may not enhance overall cognitive ability in women |
None |
| 2012-06-05 |
T-DM1 better than standard therapy in controlling breast cancer |
None |
| 2012-06-05 |
BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE |
None |
| 2012-06-05 |
New PD-1 blocking antibody shows promise against advanced kidney cancer |
3 |
| 2012-06-05 |
D-cycloserine may increase response to PTSD psychotherapy |
None |
| 2012-06-05 |
Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL |
5 |
| 2012-06-05 |
Parkinson’s vaccine: worldwide first clinical trial begins |
None |
| 2012-06-05 |
Cannabinoid therapy helps provide effective analgesia for cancer patients with pain |
None |
| 2012-06-05 |
Jennerex announces data from JX-594 clinical studies on cancer |
None |
| 2012-06-05 |
Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting |
None |
| 2012-06-05 |
Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer |
None |
| 2012-06-05 |
Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012 |
None |
| 2012-06-05 |
Alnylam announces results from ALN-VSP Phase I study on liver cancers |
3 |
| 2012-06-05 |
High doses of ginseng more effectively reduce cancer-related fatigue in patients |
None |
| 2012-06-05 |
Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma |
None |
| 2012-06-05 |
Exelixis reports data from cabozantinib phase 3 trial on MTC |
None |
| 2012-06-05 |
Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma |
None |
| 2012-06-05 |
OncoGenex announces data from OGX-427 Phase 2 study on mCRPC |
None |
| 2012-06-05 |
Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease |
3 |
| 2012-06-05 |
Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors |
None |
| 2012-06-05 |
Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012 |
5 |
| 2012-06-05 |
Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC |
None |
| 2012-06-05 |
Takeda announces updated results from orteronel phase 2 study on nmCRPC |
None |
| 2012-06-05 |
Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML |
None |
| 2012-06-04 |
Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium |
None |
| 2012-06-04 |
Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer |
None |
| 2012-06-04 |
Polynoma initiates POL 103A Phase III trial in melanoma |
None |
| 2012-06-04 |
ViroPharma initiates maribavir Phase 2 program for CMV infections |
None |
| 2012-06-04 |
Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer |
None |
| 2012-06-04 |
Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC |
None |
| 2012-06-04 |
Onyx announces data from regorafenib Phase 3 trial on GIST |
None |
| 2012-06-04 |
Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting |
None |
| 2012-06-04 |
New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL |
None |
| 2012-06-04 |
New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors |
None |
| 2012-06-04 |
ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer |
None |
| 2012-06-04 |
Many men with metastatic prostate cancer live longer on continuous hormone therapy |
None |
| 2012-06-04 |
Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease |
5 |
| 2012-06-04 |
Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients |
None |
| 2012-06-04 |
Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients |
None |
| 2012-06-04 |
Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer |
None |
| 2012-06-04 |
Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting |
None |
| 2012-06-04 |
Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC |
None |
| 2012-06-04 |
Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint |
None |
| 2012-06-04 |
Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC |
None |
| 2012-06-04 |
Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer |
None |
| 2012-06-04 |
Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas |
None |
| 2012-06-04 |
Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC |
None |
| 2012-06-02 |
ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO |
4.3 |
| 2012-06-02 |
Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer |
None |
| 2012-06-02 |
Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer |
None |
| 2012-06-02 |
Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer |
None |
| 2012-06-02 |
Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors |
None |
| 2012-06-02 |
Two pharma companies plan international trials into targeted cancer treatments in the UK |
None |
| 2012-06-02 |
LDK378 compound well-tolerated in patients with ALK+ NSCLC |
None |
| 2012-06-02 |
New medication proves effective in slowing the spread of metastatic prostate cancer |
None |
| 2012-06-02 |
PharmaNAC may be an effective therapy for some features of autism |
3 |
| 2012-06-02 |
Liver metastases predicts shorter overall survival in men with mCRPC |
None |
| 2012-06-02 |
Lilly, Kowa announce results from PREVAIL U.S. study |
None |
| 2012-06-01 |
Results from A.P. Pharma’s APF530 Phase 3 trial on CINV |
None |
| 2012-06-01 |
Beta-carotene safe to use during radiation therapy for prostate cancer |
None |
| 2012-06-01 |
ImmunoCellular to present new data from ICT-107 Phase I trial on GBM |
None |
| 2012-06-01 |
NAC reduces irritability in children with autism |
4 |
| 2012-06-01 |
Top-line results from Genzyme’s teriflunomide Phase III trial on MS |
None |
| 2012-06-01 |
NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial |
None |
| 2012-06-01 |
Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma |
None |
| 2012-06-01 |
RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials |
None |
| 2012-06-01 |
Omeros commences planned PK substudy in Phase 3 clinical program of OMS302 |
None |